Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance

BACKGROUND: Despite new and better treatments for juvenile dermatomyositis (JDM), not all patients with moderate severity disease respond adequately to first-line therapy. Those with refractory disease remain at higher risk for disease and glucocorticoid-related complications. Biologic disease-modif...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherman, Matthew A., Kim, Hanna, Banschbach, Katelyn, Brown, Amanda, Gewanter, Harry L., Lang, Bianca, Perron, Megan, Robinson, Angela Byun, Spitznagle, Jacob, Stingl, Cory, Syverson, Grant, Tory, Heather O., Spencer, Charles H., Tarvin, Stacey E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825021/
https://www.ncbi.nlm.nih.gov/pubmed/36609397
http://dx.doi.org/10.1186/s12969-022-00785-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825021/
https://www.ncbi.nlm.nih.gov/pubmed/36609397
http://dx.doi.org/10.1186/s12969-022-00785-5

Ejemplares similares